Phase II trial of XELOX plus bevacizumab for metastatic colorectal cancer.
Phase 2
Recruiting
- Conditions
- advanced colorectal cancer
- Registration Number
- JPRN-UMIN000006397
- Lead Sponsor
- agoya Surgical Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
(1)With brain metastases (2)Uncontrollable peptic ulcer disease (3)Prior chemotherapy with bevacizumab or oxaliplatin (4)Serious complications (5)Multiple malignancies to be treated (6)Severe neuropathy (7)With interstitial lung disease or pulmonary fibrosis (8)Pregnant (9)Previous history of severe drug-induced allergy (10)Disqualified by attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie XELOX and bevacizumab synergy in metastatic colorectal cancer?
How does XELOX plus bevacizumab compare to FOLFOX plus bevacizumab in metastatic CRC progression-free survival?
Which biomarkers correlate with response to XELOX-bevacizumab in RAS/RAF-mutant metastatic colorectal cancer?
What are the most common adverse events in JPRN-UMIN000006397 and strategies for their management?
How does XELOX-bevacizumab combination therapy align with other anti-VEGF regimens like FOLFIRI-bevacizumab in CRC?